In a new piece for RealClearHealth, Doug Badger and I look at the data regarding work requirement for some Medicaid recipients in Arkansas and find the shrill criticism of the program is not supported by facts. Arkansas is one of seven states that have obtained permission from the Trump administration to establish work requirements in its Medicaid program, and the administration is … [Read more...] about Medicaid and Work: Crisis in Arkansas?
Most of the real action on health reform is likely to happen in the regulatory space over the next two years, and the Trump administration can build on the opportunities it already has created with a regulatory fix that would increase access to health insurance for working families. We submitted a comment letter on Friday recommending a change to the administration’s proposed … [Read more...] about Increasing Access to Health Insurance for Working Families
U.S. District Judge Reed O’Connor’s decision striking down ObamaCare provides an opportunity for states to begin solving the mess Washington has created in their health insurance markets. My colleague Doug Badger writes that the decision gives states “new space to create policies that benefit their own residents—the sick, the healthy, and the poor. Congress should resist the urge to act in … [Read more...] about Don’t Panic: There’s Time To Get ObamaCare Replacement Right
The Trump administration has made important progress in loosening the federal government’s grip on private health insurance, freeing up more options for affordable health insurance. But the administration has veered off this free-market track with its recent proposal to, among other things, slap a form of imported price controls on a specific class of prescription drugs in Medicare. To its … [Read more...] about Trump’s Misguided Solution to Drug Prices
By Grace-Marie Turner— The Trump administration continues to work overtime to lower prescription drug costs for consumers. In response, some pharmaceutical companies have announced rollbacks of price increases, cuts in prices, price freezes, or other ways to improve affordability for patients. In the latest example, Amgen, a leading biologics company, is stepping forward to bring down prices … [Read more...] about Amgen Announces Major Price Cut For Its Breakthrough Cholesterol Drug